Business description
Idorsia Ltd is an independent biopharmaceutical company specialized in the discovery and development of small molecule therapeutics to meet significant unmet medical needs. Idorsia has a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. Idorsia directly benefits from Actelion’s 19-year history and experience, inheriting Actelion’s established and validated drug discovery engine and a strong cross-section of its development organization. Idorsia’s pipeline will be developed by its own development organization. Headquartered in Allschwil, Switzerland, Idorsia was incorporated on 2 March 2017 and was launched on 16 June 2017.
Management board & Supervisory board
| CEO |
| Jean-Paul Clozel |
| Management board |
| André C. Muller, Martine Clozel, Guy Braunstein, Alberto Gimona |
| Supervisory board |
| Jean-Paul Clozel, Mathieu Simon, Joern Aldag, Felix R. Ehrat, Srishti Gupta, Peter Kellogg, Sophie Kornowski, Sandy Mahatme, Bart Filius |
Company data
| Name: |
Idorsia Ltd |
| Address: |
Hegenheimermattweg 91,CH-4123 Allschwil |
| Phone: |
+41-58-8440000 |
| Fax: |
- |
| E-mail: |
info@idorsia.com
|
| Internet: |
https://www.idorsia.com |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12/31 |
| Free Float: |
- |
| IPO date: |
6/16/2017 |
